Tech Company Financing Transactions
Cardiokine Funding Round
On 5/1/2006, Cardiokine landed $50 million in Series B financing from F-Prime Capital, Advent International and Burrill & Company.
Transaction Overview
Company Name
Announced On
5/1/2006
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the new funds to initiate Phase lll trials for its lead product candidate Lixivaptan, a selective V2 vasopressin receptor antagonist that has demonstrated promising activity in treating hyponatremia.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
30 South 15th St. 15th Floor
Philadelphia, PA 19102
USA
Philadelphia, PA 19102
USA
Phone
Website
Email Address
Overview
CardioKine Inc. is a specialty pharmaceutical company focused on the development of pharmaceuticals for the treatment and prevention of heart failure and related cardiovascular indications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Amber Salzman
Chief Financial Officer
Mark Guerin
Chief Medical Officer
Cesare Orlandi
VP - Bus. Development
Len Selihar
VP - Regulatory Affairs
George Hemsworth
Browse more venture capital transactions:
Prev: 5/1/2006: Reconnex venture capital transaction
Next: 5/1/2006: Negevtech venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We document tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs